Fig. 2: Paired maternal, cord, and infant IgG and neutralization antibodies. | Nature Communications

Fig. 2: Paired maternal, cord, and infant IgG and neutralization antibodies.

From: Evaluation of transplacental transfer of mRNA vaccine products and functional antibodies during pregnancy and infancy

Fig. 2

A Paired maternal plasma at delivery (n = 19), cord plasma (n = 17), and infant follow-up (n = 11) by anti-SARS-CoV-2 RBD/N IgG antibody relative fluorescence units (RFU), (Spearman’s rank correlation, dotted line indicates positive cutoff value of 50 RFU). B Paired maternal plasma at delivery (n = 17), cord plasma (n = 16), and infant follow-up (n = 8) by SARS-CoV-2 label-free surrogate neutralization assay (sVNT), (Spearman’s rank correlation, dotted line indicates positive cutoff value of 25). C Paired cord plasma (n = 9) and infant follow-up plasma (n = 11) anti-SARS-CoV-2 RBD/N IgG by weeks of life. D Paired cord plasma (n = 7) and infant follow-up plasma (n = 8) label-free surrogate neutralization assay (sVNT) by weeks of life. E Paired maternal plasma at delivery (n = 5), cord plasma (n = 5), and paired maternal follow-up (n = 5) and infant follow-up plasma (n = 5) anti-SARS-CoV-2 RBD/N IgG. Two-sided p values were calculated for all test statistics. Source data are provided as a source data file.

Back to article page